The effects of a low international normalized ratio on thromboembolic and bleeding complications in patients with mechanical mitral valve replacement
- PMID: 24885719
- PMCID: PMC4019352
- DOI: 10.1186/1749-8090-9-79
The effects of a low international normalized ratio on thromboembolic and bleeding complications in patients with mechanical mitral valve replacement
Abstract
Background: Mechanical heart valve replacement has an inherent risk of thromboembolic events (TEs). Current guidelines recommend an international normalized ratio (INR) of at least 2.5 after mechanical mitral valve replacement (MVR). This study aimed to evaluate the effects of a low INR (2.0-2.5) on thromboembolic and bleeding complications in patients with mechanical MVR on warfarin therapy.
Methods: One hundred and thirty-five patients who underwent mechanical MVR were enrolled in this study. The end points of this study were defined as TEs (valve thrombosis, transient ischemic attack, stroke) and bleeding (all minor and major bleeding) complications. Patients were followed up for a mean of 39.6 months and the mean INR of the patients was calculated. After data collection, patients were divided into 3 groups according to their mean INR, as follows: group 1 (n = 34), INR <2.0; group 2 (n = 49), INR 2.0-2.5; and group 3 (n = 52), INR >2.5.
Results: A total of 22 events (10 [7.4%] thromboembolic and 12 [8.8%] bleeding events) occurred in the follow-up period. The mean INR was an independent risk factor for the development of TEs. Mean INR and neurological dysfunction were independent risk factors for the development of bleeding events. A statistically significant positive correlation was found between the log mean INR and all bleeding events, and a negative correlation was found between the log mean INR and all TEs. The total number of events was significantly lower in group 2 than in groups 1 and 3 (P = 0.036).
Conclusions: This study showed that a target INRs of 2.0-2.5 are acceptable for preventing TEs and safe in terms of bleeding complications in patients with mechanical MVR.
Similar articles
-
Achieved anticoagulation vs prosthesis selection for mitral mechanical valve replacement: a population-based outcome study.Chest. 2009 Dec;136(6):1503-1513. doi: 10.1378/chest.08-1233. Epub 2009 May 29. Chest. 2009. PMID: 19482955 Free PMC article.
-
Analysis of Anticoagulation Therapy and Anticoagulation-Related Outcomes Among Asian Patients After Mechanical Valve Replacement.JAMA Netw Open. 2022 Feb 1;5(2):e2146026. doi: 10.1001/jamanetworkopen.2021.46026. JAMA Netw Open. 2022. PMID: 35103794 Free PMC article.
-
Optimal INR level for warfarin therapy after mechanical mitral valve replacement.BMC Cardiovasc Disord. 2019 Apr 25;19(1):97. doi: 10.1186/s12872-019-1078-3. BMC Cardiovasc Disord. 2019. PMID: 31023235 Free PMC article.
-
International Normalized Ratio Targets for Left-Sided Mechanical Valve Replacement.Thromb Haemost. 2018 May;118(5):906-913. doi: 10.1055/s-0038-1637755. Epub 2018 Apr 3. Thromb Haemost. 2018. PMID: 29614524
-
Mechanical heart valve patients can manage oral anticoagulant therapy themselves.Eur J Cardiothorac Surg. 2003 Mar;23(3):292-8. doi: 10.1016/s1010-7940(02)00817-5. Eur J Cardiothorac Surg. 2003. PMID: 12614796 Review.
Cited by
-
A case of Cardiobacterium valvarum endocarditis with cerebral hemorrhage after MVR, TVP and vegetation removal operation.Ann Clin Microbiol Antimicrob. 2018 Mar 22;17(1):11. doi: 10.1186/s12941-018-0263-z. Ann Clin Microbiol Antimicrob. 2018. PMID: 29566704 Free PMC article.
-
Outcomes related to anticoagulation management for mechanical valve replacements.J Thorac Dis. 2021 May;13(5):2874-2884. doi: 10.21037/jtd-20-2562. J Thorac Dis. 2021. PMID: 34164179 Free PMC article.
References
-
- Guidelines on the management of valvular heart disease (version 2012) The Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) Eur Heart J. 2012;9:2451–96. - PubMed
-
- Bonow RO, Carabello BA, Chatterjee K, de Leon AC Jr, Faxon DP, Freed MD, Gaasch WH, Lytle BW, Nishimura RA, O'Gara PT, O'Rourke RA, Otto CM, Shah PM, Shanewise JS. 2008 focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1998 guidelines for the management of patients with valvular heart disease). Endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol. 2008;9(13):e1–142. doi: 10.1016/j.jacc.2008.05.007. - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources